Solid Biosciences Inc is a biotechnology company focused on developing innovative therapies for rare genetic diseases, particularly those affecting muscle function, with a strong emphasis on Duchenne muscular dystrophy (DMD)
The company's approach integrates advanced scientific research and clinical expertise to create novel treatments that address the underlying genetic factors of these conditions. Solid Biosciences is committed to collaborating with patients, families, and the scientific community to drive its mission of transforming the lives of individuals affected by muscular dystrophy through groundbreaking therapeutic solutions.
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQBLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results.
As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of Advanced Micro Devices, Inc. (NASDAQAMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion. AMD shares dipped 3.8% to $165.49 on Wednesday.
